company? Let’s change
that.
Don't see your company?
Create a company profileBioBlocks is a medicinal research organization that provides medicinal chemistry services and products to pharmaceutical customers.
Sterigenics, a Sotera Health company, is a global leader in comprehensive sterilization services for the medical device, pharmaceutical, food safety and advanced applications markets. With our industry recognized scientific and technological expertise we help to ensure the safety of millions of patients and healthcare practitioners around the world every year. We offer our customers a complete range of outsourced terminal sterilization services, primarily using the three major sterilization technologies: gamma irradiation, ethylene oxide processing and electron beam irradiation and other technologies including X-Ray and nitrogen dioxide. Our global integrated network includes 48 facilities in 13 countries to ensure we provide the flexibility and redundancy needed. We are committed to addressing the growing need for sterilization in many parts of the world and partnering with our customers to eliminate threats to human health. Safeguarding Global Health® - with every product we sterilize.
Sumitovant is a global biopharma company with offices in New York and London. It is the parent company of five biopharmaceutical companies: Myovant Sciences, Urovant Sciences, Enzyvant Therapeutics, Altavant Sciences and Spirovant Sciences. Our companies have a robust pipeline of innovative drug treatments targeting a broad range of diseases. • Sumitovant’s Digital Innovation approach integrates key skill sets, data sets and analytic tools to provide real answers to pharma’s most critical questions. With our tech-enabled approach to drug discovery, development and commercialization, we remove friction and accelerate every aspect of the process to bring promising new compounds to market. Sumitovant is wholly owned by Sumitomo Dainippon Pharma. Together, the Sumitomo Dainippon Pharma group of companies closely collaborate to expedite the discovery, development, and commercialization of truly innovative treatments. This collaboration harnesses the expertise of each organization with the goal of significantly improving patient outcomes and shareholder return.
Founded in 2009, Flagship Biosciences, Inc., is a technology-driven spatial biology and biomarker services company delivering the most accurate and informative data available. We are revolutionizing biomarker analysis to improve drug development and diagnostics using the power of AI with a consultative approach. Our services and technology dramatically improve on the data and interpretation from traditional methods, eliminating variability associated with typical biomarker assessments, and bringing new insights to analysis results. We provide expert scientific consultation for every client. Our team interprets results, contextualizes biology, and identifies the best course for success.
VeriSIM Life is building AI enabled biosimulation models. VeriSIM will tackle one of the biggest obstacles of drug development: animal testing for drug development. Animal testing is slow, ethically questionable, and doesn't act as much of a filter: 92% of all drug candidates that pass this preclinical testing never make it to market. VeriSIM's solution is to create disease-specific biosimulation models, which allow researchers at pharma companies to model in software how a drug will interact in animals. This will allow researchers to test 1000x more potential candidates in the same unit of time, ensuring that drugs that do make it to (human) clinical trials are far more likely to work, and therefore saving millions in annual costs.
We’re out to change the course of medical science. Are you ready to rise to the challenge? Premier Research is not about being everything to everyone. Instead, our deep, focused expertise targets the therapeutic areas and indications where today’s biotech and specialty pharma pioneers are doing the most amazing work. We’re 1,500 employees strong and operate in more than 20 countries, delivering unmatched expertise, operational skills, and dedication to meeting customers’ most challenging needs. Join us and meet some of the brightest minds in clinical development today — people who apply their best thinking to every project, recognizing that what they do significantly affects the lives and well-being of customers, patients, physicians, and colleagues. You’ll enjoy great benefits and very flexible working conditions in a company that values your contributions, rewards your achievements, and is committed to helping you reach your full potential. Are you ready to make a real difference and help us transform this exciting industry? Follow our company page for more information about us and the work we do, and check out our current openings for your next career move!
CIS Biotech is a research and development company bringing disease-associated biomarkers and in vitro diagnostic tools to the marketplace.
As much as 99% of bacteria in the natural world can’t be seen with the human eye and are unknown. Uncovering the secrets of microbes & biodiversity should be the scientific quest for our era. BiOWiSH® provides industry-leading biotechnology solutions for the agriculture and environmental management industries. Our product range is proven to deliver consistent performance globally for agricultural applications, aquaculture production, and the water treatment industry. Led by former P&G scientists and senior executives based in Cincinnati, Ohio, the company has formed partnerships with leading research institutions around the world, to explore and develop a wide range of commercial applications for its proprietary technology. BiOWiSH Technologies was formed to commercialize composite biocatalysts and probiotics derived from a unique blend of naturally occurring microorganisms, enzymes, and co-factors. These materials enhance the rate and efficiency of biochemical systems over a wide range of environmental conditions.
Stemedica Cell Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of progenitor cell and protein therapeutics for underserved medical conditions. Stemedica has developed a proprietary manufacturing technology platform that produces allogeneic progenitor cell products with intellectual property protection under a low-oxygen, low-tension environment in a cGMP-compliant manufacturing facility. The company's lead drug candidate, ischemia-tolerant mesenchymal stem cells, or itMSCs, is an allogeneic progenitor cell therapy currently in clinical development for the treatment of ischemic stroke and Alzheimer’s disease. The company’s second drug candidate, ischemia-tolerant neural progenitor cells, or itNSCs, is an allogeneic cell therapy currently in development for spinal cord injury. In addition, Stemedica is developing progenitor multi-cell therapy (itMSCs and itNSCs) for ischemic stroke and progenitor cell and protein combination therapy for Alzheimer’s disease. More information on Stemedica may be found at www.stemedica.com.
Established in 2019, BioCentriq is a full-service, New Jersey-based CDMO for cell and gene therapy, focusing on all stages of process development and clinical manufacturing. With over 90 scientists, engineers, analysts, and manufacturing specialists, we have the quality systems and infrastructure required to support the release of both autologous and allogeneic drug products. BioCentriq also specializes in viral vector process development and manufacturing with expertise in a variety of cell and vector types. Our 35,000 square feet of facilities includes four, soon to be five, ISO-7 certified GMP manufacturing suites, a fully equipped process development laboratory, quality control and analytical method development laboratories, and training facilities. We also operate the only McKinsey-owned Innovation & Learning Center designed to explore the application of industry 4.0, digital and lean manufacturing disciplines to life sciences.
Serving the scientific community since 1925, Labconco Corporation manufactures laboratory equipment, specializing in ventilation products such as chemical fume hoods and blowers, ductless fume enclosures, balance enclosures, HEPA-filtered biological safety cabinets (BSCs), clean benches, glove boxes, and laboratory animal research enclosures. Other product lines include glassware washers, forensic enclosures, centrifugal concentrators, lyophilizers, evaporators, and water purification systems. Custom designed products are also available. Protecting your laboratory environment is the foundation of Labconco's product development efforts, and every Labconco product is designed with safety in mind. Its products' performance meets or exceeds industry standards including ANSI/ASHRAE 110-1995, NSF Standard 49 and UL 61010-1. Labconco employs more than 200 associates, every one taking pride in providing outstanding customer service. Labconco is ISO 9001:2008 certified, one measure of its commitment to quality and consistency in design and manufacturing. Through a worldwide network of distributors, Labconco serves a variety of laboratory customers around the globe, including universities, research centers, hospitals and government agencies.
Amnio Technology is a company based out of 22510 N 18TH DR, PHOENIX, Arizona, United States.
Biotechnology startup developing automated species identification technologies for AgTech, BioTech, and Environmental monitoring sectors.
ImmunoMet Therapeutics is a biopharmaceutical company that develops and commercializes oncology products for cancer patients.
UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com.
We aim to advance urologic patient care through bold innovation, based on diversity of thought, openness to new ideas, adaptation to change, integrity and compassion. We develop innovative therapies and participate in exceptional licensing opportunities. Our goal is to be the leading specialty company: recognized and trusted by patients and providers for our commitment to urology. Urologic conditions can have a major impact on daily life, with those affected often suffering in silence as their conditions are overlooked, misunderstood or not adequately treated. Read more about our community guidelines: https://urovant.com/community-guidelines/
RxResults is a pharmacy benefits risk management company developing a suite of clinical tools to reduce cost.
LyGenesis is an organ regeneration company.
AgonOx is a cure for many types of cancer will be found through harnessing the power of the immune system
Miromatrix Medical is engaged in the development of fully biological human organs and organ-derived biological products.